Mika Ala‐Korpela et al.: Characterization and molecular detection of atherothrombosis by magnetic resonance—potential tools for individual risk assessment and diagnostics
Annals of Medicine. 2006;38:322–336
Page 331, is incorrect (same as figure 6 but in black & white). The correct Figure 5 is shown below:
Figure 5. An application of a high‐density lipoprotein (HDL)‐like nanoparticle contrast agent for macrophage‐targeted in vivo magnetic resonance imaging (MRI). Phospholipid‐based contrast agent Gd‐DTPA‐DMPE and NBD‐DPPE‐labelled phospholipid for fluorescence confocal microscopy were used for the reconstruction of HDL. The MR images of an apolipoprotein E knockout mouse at 1.5 T illustrate the pre‐ and 24 h post‐injection of contrast agent at a rHDL dose of 4.36 μmol/kg. White arrows point to the abdominal aorta; the insets denote a magnification of the aorta region. (Modified from Frias et al. 2004 (52) with permission.)
